Guardant Health and Nuvalent have struck a multi-year collaboration to build and commercialize oncology companion diagnostics. The deal will leverage Guardant’s tissue and liquid biopsy portfolio to support certain Nuvalent global clinical oncology studies and to evaluate assay opportunities that could support regulatory approvals for Nuvalent pipeline candidates. The collaboration also covers commercialization across key markets if the relevant Nuvalent therapies receive approval. Financial terms were not disclosed. Nuvalent is currently advancing ALK inhibitor neladalkib and has additional investigational programs in ROS1-positive and HER2-altered non-small cell lung cancer.